Related Experiment Videos
[Aranoza -- a new Russian antineoplastic drug]
V A Gorbunova1, N F Orel, O V Semina
1N.N. Blokhin Center for Oncology Research, Russian Academy of Medical Sciences, Moscow.
Voprosy Onkologii
|February 6, 2002
Summary
Aranoza shows effectiveness in treating various cancers, including uterine sarcoma and melanoma, though myelosuppression limits dosage. Further clinical trials are ongoing for combined therapy approaches.
Area of Science:
- Oncology
- Pharmacology
Background:
- Myelosuppression is a significant toxicity limiting aranoza dosage.
- Aranoza has demonstrated efficacy in clinical trials for several cancer types.
Purpose of the Study:
- To evaluate the effectiveness of aranoza in treating various malignancies.
- To explore potential applications of aranoza in chemoimmunotherapy and intraarterial infusions.
Main Methods:
- Stage II clinical studies were conducted.
- Treatment involved aranoza for specific cancers.
Main Results:
- Aranoza proved effective in uterine sarcoma, head and neck cancer, breast cancer, Hodgkin's disease, and lymphosarcoma.
- Complete regression was observed in approximately 12% of melanoma cases.
- Positive outcomes are anticipated for chemoimmunotherapy in untreated patients and intraarterial infusions for localized extremity lesions.
Conclusions:
- Aranoza is an effective agent for multiple cancer types.
- Further research is warranted for combined modality therapies and specific administration routes.